GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Benazepril hydrochloride tablets

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Lotensin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Lotensin - product and source limitations

Check serum potassium and renal function. This adult starting dose cannot be used as a pediatric regimen.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Lotensin - product and source limitations

Official source

Lotensin - labeled renal guidance

Renal action and limits

Benazepril (Lotensin), adult oral tablets for hypertension
Indexed GFR/eGFR, mL/min/1.73 m2

Action or finding
At GFR <30 mL/min/1.73 m2, the adult starting dose is 5 mg once daily. Titrate against blood pressure to a maximum of 40 mg/day.
Limits and monitoring
Check serum potassium and renal function. This adult starting dose cannot be used as a pediatric regimen.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 10, effective 2025-09-30; posted Oct 02, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Benazepril (Lotensin), adult oral tablets for hypertension
Renal measure
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 10, effective 2025-09-30; posted Oct 02, 2025
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2, renal impairment

At GFR <30 mL/min/1.73 m2, the adult starting dose is 5 mg once daily. Titrate against blood pressure to a maximum of 40 mg/day. Check serum potassium and renal function. This adult starting dose cannot be used as a pediatric regimen.

Source revision: DailyMed SPL version 10, effective 2025-09-30; posted Oct 02, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

Lotensin - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Benazepril (Lotensin), adult oral tablets for hypertension

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Lotensin - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Lotensin - product and source limitations

Check serum potassium and renal function. This adult starting dose cannot be used as a pediatric regimen.

How to use this: Apply only to the stated formulation, indication and renal population.

Lotensin - labeled renal guidanceLotensin - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeLotensin - labeled renal guidanceLotensin - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

For Hypertensive Patients with Renal Impairment: For patients with a creatinine clearance <30 mL/min/1.73 m2 (serum creatinine >3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablet once daily. Dosage may be titrated upward until blood pressure is controlled or to a maximum total daily dose of 40 mg.

Normal renal function: The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.

GRPH-general-benazepril-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Lotensin - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Benazepril (Lotensin), adult oral tablets for hypertension

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 10, effective 2025-09-30; posted Oct 02, 2025
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2, renal impairment

At GFR <30 mL/min/1.73 m2, the adult starting dose is 5 mg once daily. Titrate against blood pressure to a maximum of 40 mg/day. Check serum potassium and renal function. This adult starting dose cannot be used as a pediatric regimen.

RDM73-lotensin-official-1 · Source locator: Renal guidance: 2, renal impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 10, effective 2025-09-30; posted Oct 02, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
4884be0da9594c7782feb2a75da4ec3401d8a82b17c74f6ae19cbbe3bd3e6cf0
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Lotensin - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Benazepril (Lotensin), adult oral tablets for hypertension

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror specifies an initial daily 5 mg dose in this GFR band.

RDM73-lotensin-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lotensin-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
b081cf2cfdcdc6408bbbb59802677c273122ca035f63714089b0f8c9f7806cb4

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 4
Local text SHA-256
714e05e8127db559caa7eae78fde4abd2a9e7d5f47598a1b3096ba05c090f376
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top